Picard Medical Inc (PMI) — 13F Holders Deep Dive (Q2 2026)

No AI summary for this filing type

Picard Medical, Inc. (PMI) announced on July 22 that NYSE American accepted its compliance plan to address potential delisting due to low stockholders' equity and recent losses. The company had reported stockholders' equity of $3.8 million as of December 31, 2025, followed by a deficit of $1.4 million as of March 31, 2026, along with losses in three of its last four fiscal years. Under the accepted plan, PMI can continue trading on the exchange subject to meeting specific milestones and quarterly reviews, with up to 18 months to fully regain compliance.

Picard Medical, Inc. announced a 1-for-50 reverse stock split. The company filed an amendment to its charter to combine every 50 existing shares into one share. The split will become effective after market close on July 31, 2026, and the stock will start trading on a split-adjusted basis on NYSE American under the same ticker 'PMI' on August 3, 2026. No fractional shares will be issued; instead, any fractional shares will be rounded up to the nearest whole share.

At Picard Medical's annual meeting on July 17, 2026, shareholders voted on six proposals and approved all of them. The four nominated directors were each elected with over 54 million votes in favor. An advisory vote on executive compensation passed, and shareholders chose an annual frequency for these votes. The company also got approval to amend its charter to authorize a reverse stock split (at a ratio between 1:15 and 1:50, with the board deciding the exact ratio), to create a Class B common stock with 20 votes per share, and to ratify MaloneBailey LLP as auditor for 2026.

Picard Medical, Inc. filed an amendment to its earlier 8-K to correct a press release that accompanied the announcement of a pre-recorded presentation for its 2026 annual meeting of stockholders. The corrected version is included as Exhibit 99.1 of this amendment.

Picard Medical filed an amended 8-K to correct the committee assignments for Dr. Joe Xiao, who was appointed to the board on June 23, 2026. He will serve on the Compensation Committee and the Nominating and Corporate Governance Committee. Dr. Xiao will receive standard non-employee director compensation and has signed a standard indemnification agreement. There are no special arrangements or reportable transactions.

No AI summary for this filing type

No AI summary for this filing type

AI summary pending